Literature DB >> 28192275

First-trimester medical abortion practices in Canada: National survey.

Edith R Guilbert1, Althea S Hayden2, Heidi E Jones3, Katharine O'Connell White4, E Steven Lichtenberg5, Maureen Paul6, Wendy V Norman7.   

Abstract

OBJECTIVE: To understand the current availability and practice of first-trimester medical abortion (MA) in Canada.
DESIGN: Using public sources and professional networks, abortion facilities across Canada were identified for a cross-sectional survey on medical and surgical abortion. English and French surveys were distributed by surface or electronic mail between July and November 2013.
SETTING: Canada. PARTICIPANTS: A total of 94 abortion facilities were identified. MAIN OUTCOME MEASURES: Descriptive statistics on MA practice and facility and provider characteristics, as well as comparisons of MA practice by facility and provider characteristics using χ2 and t tests.
RESULTS: A total of 78 of 94 (83.0%) facilities responded. Medical abortion represented 3.8% of first-trimester abortions reported (2706 of 70 860) in 2012. Among the facilities offering MA, 45.0% performed fewer than 500 first-trimester abortions a year, while 35.0% performed more than 1000. More MAs were performed in private offices or ambulatory health centres than in hospitals. Sixty-two physicians from 28 of 78 facilities reported providing first-trimester MA; 87.1% also provided surgical abortion. More than three-quarters of MA physicians were female and 56.5% were family physicians. A preponderance (85.2%) of providers offered methotrexate with misoprostol. Nearly all physicians (90.3%) required patients to have an ultrasound before MA, and 72.6% assessed the completion of the abortion with ultrasonography. Most physicians (74.2%) offered MA through 49 days after the onset of the last menstrual period, and 21.0% offered MA through 50 to 56 days; 37.1% reported providing MA to patients who lived more than 2 hours away. Four physicians from 1 site provided MA via telemedicine.
CONCLUSION: In Canada, MA provision using methotrexate and misoprostol is consistent with best-practice guidelines, but MA is rare and its availability is unevenly distributed. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Year:  2016        PMID: 28192275      PMCID: PMC4830676     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  21 in total

1.  Comparison of four regimens of misoprostol after methotrexate for early abortion.

Authors:  Ellen Wiebe; Wendy Hempstock
Journal:  Int J Gynaecol Obstet       Date:  2008-03-04       Impact factor: 3.561

Review 2.  Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound?

Authors:  Bliss Kaneshiro; Alison Edelman; Robyn K Sneeringer; Rodolfo Gomez Ponce de Leon
Journal:  Contraception       Date:  2010-09-17       Impact factor: 3.375

3.  Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy.

Authors:  M D Creinin; E Vittinghoff; L Keder; P D Darney; G Tiller
Journal:  Contraception       Date:  1996-06       Impact factor: 3.375

4.  Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol.

Authors:  M D Creinin
Journal:  Am J Obstet Gynecol       Date:  1996-02       Impact factor: 8.661

5.  Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated.

Authors:  Wesley Clark; Tanya Panton; Louisa Hann; Marji Gold
Journal:  Contraception       Date:  2006-12-22       Impact factor: 3.375

6.  Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation.

Authors: 
Journal:  BMJ       Date:  1993-08-28

7.  What happens when we routinely give doxycycline to medical abortion patients?

Authors:  Laura J Frye; Erica Chong; Beverly Winikoff
Journal:  Contraception       Date:  2014-09-15       Impact factor: 3.375

8.  Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.

Authors:  Ellen Wiebe; Sheila Dunn; Edith Guilbert; Francis Jacot; Lisa Lugtig
Journal:  Obstet Gynecol       Date:  2002-05       Impact factor: 7.661

9.  Effect of mifepristone on abortion access in the United States.

Authors:  Lawrence B Finer; Junhow Wei
Journal:  Obstet Gynecol       Date:  2009-09       Impact factor: 7.661

10.  Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion.

Authors:  Ellen R Wiebe; Konia Trouton
Journal:  Contraception       Date:  2004-12       Impact factor: 3.375

View more
  6 in total

1.  Abortion services and providers in Canada in 2019: results of a national survey.

Authors:  Regina M Renner; Madeleine Ennis; Damien Contandriopoulos; Edith Guilbert; Sheila Dunn; Janusz Kaczorowski; Elizabeth K Darling; Arianne Albert; Claire Styffe; Wendy V Norman
Journal:  CMAJ Open       Date:  2022-09-27

2.  Could implementation of mifepristone address Canada's urban-rural abortion access disparity: a mixed-methods implementation study protocol.

Authors:  Wendy V Norman; Sarah Munro; Melissa Brooks; Courtney Devane; Edith Guilbert; Regina Renner; Tamil Kendall; Judith A Soon; Ashley Waddington; Marie-Soleil Wagner; Sheila Dunn
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

3.  Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers.

Authors:  Courtney Devane; Regina M Renner; Sarah Munro; Édith Guilbert; Sheila Dunn; Marie-Soleil Wagner; Wendy V Norman
Journal:  Pilot Feasibility Stud       Date:  2019-11-08

4.  Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.

Authors:  Enav Z Zusman; Sarah Munro; Wendy V Norman; Judith A Soon
Journal:  BMJ Open       Date:  2022-10-07       Impact factor: 3.006

5.  First trimester medication abortion practice in the United States and Canada.

Authors:  Heidi E Jones; Katharine O'Connell White; Wendy V Norman; Edith Guilbert; E Steve Lichtenberg; Maureen Paul
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

6.  Pharmacist dispensing of the abortion pill in Canada: Diffusion of Innovation meets integrated knowledge translation.

Authors:  Sarah Munro; Kate Wahl; Judith A Soon; Edith Guilbert; Elizabeth S Wilcox; Genevieve Leduc-Robert; Nadra Ansari; Courtney Devane; Wendy V Norman
Journal:  Implement Sci       Date:  2021-08-03       Impact factor: 7.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.